| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.16 | 0.01 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.02 |